Management Guidance Tracker
Tracking AXT's quarterly revenue guidance vs. actuals across the 2020–2025 compound semiconductor cycle. Coverage includes InP substrates for AI silicon photonics, China export permit dynamics, and the long-pending Tongmei STAR Market IPO.
China Export Permit Context: Since Aug 2023 (gallium/germanium) and Feb 2025 (indium phosphide), AXT's China-manufactured wafers require Ministry of Commerce export permits (~60-business-day cycle). Permit timing has been the primary source of guidance volatility in 2024–2025.
24
Quarters Tracked (2020–2025)
80%
Hit Rate (Exceeded + Met)
$60M+
InP Backlog (Q4 2025)
Guidance Track Record
Exceeded — Above guidance high (6)
Not Met — Below low end (3)
Quarterly Revenue: Guidance vs. Actual
Full Quarterly History
| Quarter | Guide Low | Guide High | Actual | Verdict | Notes |
|---|
Guidance ranges for Q1–Q3 2020, Q4 2022, Q1 2023, and parts of FY2024 not publicly retrievable from earnings press releases — marked "—". Sources: AXT 8-K filings (CIK 1051627), earnings releases via BusinessWire / GlobeNewswire, Motley Fool / Seeking Alpha call transcripts. All figures in $M.
Strategic Timeline
Jan 2022
Tongmei STAR Market IPO Filed
Application filed with Shanghai Stock Exchange. Tongmei is AXT's operating subsidiary holding all wafer manufacturing.
Jul 2022
SSE Approves Tongmei IPO
Next gate: CSRC approval. Accepted for CSRC review Aug 2022.
2022 Peak → 2023 Trough
Cyclical Downturn
Revenue collapsed from $141M (FY2022) to $76M (FY2023) on consumer/5G weakness.
Aug 2023
China Imposes Gallium & Germanium Export Controls
Permits required for overseas GaAs and Ge shipments; creates structural shipping friction.
2024
Recovery Begins — InP Emerges as Lead
FY2024 revenue $99.4M; InP demand accelerating on AI / silicon photonics.
Dec 2024
Antimony & Critical Materials Controls Tightened
Further China restrictions on strategic materials.
Feb 2025
InP Added to China Export Control List
Each InP shipment now requires individual Ministry of Commerce permit — ~60-business-day processing.
Q2 2025
Guidance Missed on Permit Delays
Revenue $18.0M vs. $20–22M guidance; awaiting InP permit approvals.
Nov 2025 / Q3 2025
Permits Granted — Revenue Surges 250% Sequentially on InP
Q3 2025 revenue $28M vs. $19–21M guide. InP revenue jumps sharply as backlog releases.
Dec 2025
~$100M Capital Raise
To fund doubling of Beijing Tongmei InP wafer capacity by end 2026.
Feb 2026
Q4 2025 Results & Q1 2026 Guide
Q4 2025: $23M revenue (in $22.5–23.5M guide). Q1 2026 guide: $26M+. InP backlog >$60M.
Management Insights — Recent Earnings Calls
Commentary from CEO Dr. Morris Young and CFO Gary Fischer across Q4 2023 through Q4 2025 earnings calls. Central theme: AI-driven InP demand is structural, but China export permits gate delivery.
"We are 40% of the Indium Phosphide supply chain, and we have the best quality material."
— Morris Young, CEO (Q3 2025)
"The massive AI infrastructure buildout is the primary driver for EML and silicon photonics-based optical transceivers."
— Morris Young, CEO (Q3 2025)
"The most significant gating factor in our growth in Q4 and beyond is the success and timing of getting export permits."
— Gary Fischer, CFO (Q3 2025)
"We could double our capacity on Indium Phosphide in about nine months' time… about $10 to $15 million."
— Morris Young, CEO (Q3 2025)
Strategic Themes
InP Is the Growth Engine
~40% market share in indium phosphide substrates. Q3 2025 InP revenue jumped ~250% sequentially. Backlog above $60M as of Q4 2025 — multi-year AI silicon photonics visibility.
Export Permits = Binary Risk
~60-business-day processing for InP permits. Q2 2025 miss driven entirely by delayed permits; Q3 2025 surge driven by permits released. Single largest source of guidance volatility.
AI / Silicon Photonics Tailwind
800G and 1.6T optical transceivers in data-center rack interconnects require InP-based EML lasers. Order demand could 2x in 2026 and another 2x in 2027 per management.
Tongmei STAR IPO Stalled
Pending CSRC approval since Aug 2022. Over 4 years in review. $49M redemption overhang from Chinese PE investors tied to IPO outcome.
Capacity Ramp Funded
~$100M raised Dec 2025 to double Beijing Tongmei InP capacity by end-2026. Smaller $10–15M add-on can double capacity in 9 months if demand requires.
GaAs / Ge Secondary
Germanium weak (Q3 2025 Ge revenue only $0.64M, down from $1.5M). GaAs lumpy. Management acknowledges these legacy segments won't drive growth.
70% US Tariff Pressure
Wafer imports to US face 70% tariffs; North America revenue dropped from ~8% (FY2024) to ~2% (FY2025) of total.
Competition Narrow But Real
Sumitomo ~30% InP share, Freiberger, JX Nippon. AXT's moat is low etch-pit density quality & vertically integrated China raw-material ventures.
Bull vs. Bear Case
Bull Case
- InP backlog >$60M; multi-year AI photonics tailwind.
- 40% market share at supply chain chokepoint.
- Capacity doubling funded — direct line to higher 2026/2027 revenue.
- Export permits now flowing; Q3 2025 proved the model.
- $40M/qtr run-rate could support ~35% gross margin.
- Tongmei IPO if approved unlocks value & clears redemption overhang.
Bear Case
- China export permits remain a quarterly black box.
- US-China escalation could re-restrict InP permits.
- Tongmei IPO 4+ years stalled — approval not assured.
- GaAs/Ge contribution shrinking; all eggs in InP basket.
- Sumitomo and JX Nippon are well-capitalized at larger scale.
- 70% US tariffs permanently compress N.A. margins.
Recent Annual Performance
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|
| Revenue ($M) | $141.1 | $75.8 | $99.4 | $88.3 |
| Net Income / (Loss) ($M) | slight profit | ~($30) | ($11.6) | ~($17) |
| EPS (GAAP) | ~$0.03 | ~($0.70) | ($0.27) | ~($0.40) |
| InP Growth Focus | Peak cycle | Trough | Recovery | Permit-gated surge |